Hypoglycaemia - REdefining SOLutions for better liVEs
Hypo-RESOLVE logo


Start Date
End Date
IMI2 - Call 10
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
13 450 057
EFPIA in kind
10 316 000
Associated Partners
3 008 525
Total Cost
26 774 583


Many diabetes patients experience hypoglycaemia, when their blood sugar levels become too low. Symptoms include behavioural changes, memory loss and confusion, which can result in accidents and falls and, in the worst cases, in hospitalisation or death. Worries about hypoglycaemia represent a serious psychological burden for people with diabetes.

Despite its seriousness, little is known about hypoglycaemia. The Hypo-RESOLVE project aims to change that by adding to our understanding of the underlying causes of the condition, as well as its predictors and consequences. They will also analyse the financial costs of hypoglycaemia. Ultimately, the hope is that the project results will pave the way for new, better treatments for people with diabetes that will help them to maintain healthy blood sugar levels.

Achievements & News

Constant threat of 'hypos' takes heavy toll on people with diabetes
September 2020

The Hypo-RESOLVE project wants to single out the risk factors for severe hypoglycaemic episodes, where diabetes patients’ blood sugar levels fall to dangerously low levels. ###Although there are certain widely recognised risk factors for hypoglycaemia like exercise, skipped meals or insulin dosing errors, hypoglycaemic episodes very often also occur quite unexpectedly. If a ‘hypo’ occurs, you have to act quickly to bring your glucose levels back to normal and make sure you’re not a threat to yourself.

Needless to say, this often interferes directly with daily activities. Episodes can even occur without causing any symptoms, and sometimes recovery is spontaneous. Not uncommonly, a partner or family member recognises it before the patient does. ‘In the long term,’ says Hypo-RESOLVE coordinator Bastiaan de Galan of the Radboud University Medical Centre in Nijmegen, ‘hypo events can cause fear and avoidant behaviour, which makes overall glucose control even more difficult. Severe episodes can increase the risk of cardiovascular disease, although we don’t know yet whether this relation is causal.’

The Hypo-RESOLVE project wants to find out more about the mechanisms of hypoglycaemic episodes beyond what is already known, including their effect on the psychosocial well-being of people who experience them. In an interview with the IMI Programme office, Bastiaan de Galan and Jill Carlton of the University of Sheffield describe how the project is working to tackle the challenge of hypoglycaemic episodes.

Find out more

Participants Show participants on map

EFPIA companies
  • Abbott Diabetes Care, Alameda, United States
  • Eli Lilly And Company LTD, Basingstoke, United Kingdom
  • Medtronic International Trading SARL, Tolochenaz, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
Universities, research organisations, public bodies, non-profit groups
  • Centre Hospitalier Universitaire Montpellier, Montpellier, France
  • King'S College London, London, United Kingdom
  • Medizinische Universitat Graz, Graz, Austria
  • Region Hovedstaden, Hilleroed, Denmark
  • SIB Institut Suisse De Bioinformatique, CH-660-0733998-3, Genève, Switzerland
  • Stichting Radboud Universitair Medisch Centrum, Nijmegen, Netherlands
  • Syddansk Universitet, Odense, Denmark
  • The University Of Edinburgh, Edinburgh, United Kingdom
  • The University Of Sheffield, Sheffield, United Kingdom
  • Universita Degli Studi Di Padova, Padova, Italy
  • University Of Dundee, Dundee, United Kingdom
  • University Of Leicester, Leicester, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Eurice European Research And Project Office GMBH, Saarbrücken, Germany
Associated partners
  • Federation Internationale Du Diabete, Brussels, Belgium
  • Jdrf International, New York, United States
  • The Leona M. And Harry B. Helmsley Charitable Trust, New York, United States
  • Unitio Inc, Boston, United States
Third parties
  • Sheffield Teaching Hospitals Nhs Foundation Trust, Sheffield, United Kingdom
  • University Hospitals Of Leicester Nhs Trust, Leicester, United Kingdom
Project leader
Bastiaan De Galan
Stichting Radboud Universitair Medisch Centrum
Project co-leader
Matthias Müllenborn
Novo Nordisk